Quince Therapeutics, Inc. — Form 8-K
Filed October 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Quince Therapeutics filed an 8-K on 2026-10-02 disclosing Item 5.02 events: departure of a director or officer and/or appointment of officers with compensatory arrangements. The filing provides no specific names, dates of departure/appointment, compensation amounts, share counts, or details of arrangements — only that such events occurred as of the 2026-09-30 reporting date.
Why this rating
Leadership transitions are common; filing lacks specifics. Unable to assess materiality without names, amounts, or context relative to company's $64M market cap.
Extracted items
See more from October 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.